This paper explores the processes through which an organizational story acquires mythological status within an organizational field. To this end, I analyse a story of a successful case of academic technology transfer that gained mythological status in the field of higher education in Israel: the commercialization of the innovative pharmaceutical drug Copaxone. I identify three concurrent processes of mythologizing work: organizational storytelling, media diffusion and reconstruction, and field-level retelling and countering. I argue that myth-making is a collective work, in which an organizational story is shaped not only through the strategic rhetorical work of managers but also through interpretations and modifications by the media as well as other actors in the field. The myth of Copaxone, as it is currently told in the field of higher education in Israel, is a complex assemblage of the organizational story and various counter-narratives. I further suggest that this myth not only serves to naturalize and reinforce academic patenting, but also constitutes a discursive space for reflections about the ambiguities inherent in academic commercialization.
AndrewsM. (2002). Introduction: Counter-narratives and the power to oppose. Narrative Inquiry, 12, 1–6.
4.
AntebyM.MolnarV. (2012). Collective memory meets organizational identity: Remembering to forget in a firm’s rhetorical history. Academy of Management Journal, 55, 515–540.
5.
BambergM. G. W. (2004). Considering counter narratives. In BambergM. G. W.AndrewsM. (Eds.), Considering counter narratives: Narrating, resisting, making sense (pp. 351–371). Amsterdam: J. Benjamins.
6.
BarthesR. (1972). Mythologies. London: Jonathan Cape.
7.
BarthesR. (1982). Myth today. In SontagS. (Ed.), A Barthes reader (pp. 93–149). New York: Hill and Wang.
8.
BathurstR. J.MoninN. (2010). Finding myth and motive in language: A narrative of organizational change. Journal of Management Inquiry, 19, 262–272.
9.
BermanE. P. (2008). Why did universities start patenting? Institution-building and the road to the Bayh-Dole Act. Social Studies of Science, 38, 835–871.
10.
Biotech International (2000) Commercial potential and the Weizmann Institute of Science. Biotech International: The European Magazine for the Life Sciences Industry, 12(6), 14–15.
11.
BojeD. M. (1995). Stories of the storytelling organization: A postmodern analysis of Disney as ‘Tamara-Land’. Academy of Management Journal, 38, 997–1035.
12.
BrownA. D.HumphreysM. (2006). Organizational identity and place: A discursive exploration of hegemony and resistance. Journal of Management Studies, 43, 231–257.
13.
BrownA. D.ThompsonE. R. (2013). A narrative approach to strategy-as-practice. Business History, 55, 1143–1167.
14.
CalvertJ. (2006). What’s special about basic research?Science, Technology, & Human Values, 31, 199–220.
COP 1 (Copaxone): The story of a drug (1997). Interface (Weizmann Institute Magazine), (Spring-Summer), 16–17.
17.
CsapoE. (2005). Theories of mythology. Hoboken, NJ: Wiley-Blackwell.
18.
DeetzS. (1992). Democracy in an age of corporate colonization: Developments in communication and the politics of everyday life. Albany, NY: SUNY Press.
19.
DotyW. G. (2000). Mythography: The study of myths and rituals. Tuscaloosa: University of Alabama Press.
20.
Drug pioneers. (2009). Interface, Spring-Summer, 38.
21.
DureposG.Helms MillsJ.MillsA. J. (2008). Flights of fancy: Myth, monopoly and the making of Pan American Airways. Journal of Management History, 14, 116–127.
22.
EvansJ. (2010). Industry collaboration, scientific sharing, and the dissemination of knowledge. Social Studies of Science, 40, 757–791.
23.
FeyerabendP. (1975). Against method. London: Verso.
24.
FletcherJ. K.BailynL.Blake-BeardS. (2009). Practical pushing: Creating discursive space in organizational narratives. In CoxJ. W.LeTrent-JonesT. G.VoronovM.WeirD. (Eds.), Critical management studies at work: Multidisciplinary approaches to negotiating tensions between theory and practice (pp. 82–93). Cheltenham, UK: Edward Elgar.
25.
FosterW. M.CoraiolaD. M.SuddabyR.KroezenJ.ChandlerD. (2016). The strategic use of historical narratives: A theoretical framework. Business History, 59, 1176–1200.
26.
FosterW. M.SuddabyR.MinkusA.WiebeE. (2011). History as social memory assets: The example of Tim Hortons. Management & Organizational History, 6(1), 101–120.
27.
Habib-ValdhornS. (2013). Check-up on Teva. Globes [online], Israel Business News. April17.
28.
HellgrenB.LöwstedtJ.PuttonenL.TienariJ.VaaraE.WerrA. (2002). How issues become (re)constructed in the media: Discursive practices in the AstraZeneca merger. British Journal of Management, 13, 123–140.
29.
HermoniO. (2004). The millionaire professors of the Weizmann Institute. Haaretz, July4 [Hebrew].
30.
HobsbawmE.RangerT. (1983). The invention of tradition. Cambridge, UK: Cambridge University Press.
31.
KippingM.WadhwaniR. D.BucheliM. (2014). Analyzing and interpreting historical sources: A basic methodology. In BucheliM.WadhwaniR. D. (Eds.), Organizations in time: History, theory, methods (pp. 305–329). Oxford: Oxford University Press.
32.
KjaerP.LangerR. (2005). Infused with news value: Management, managerial knowledge and the institutionalization of business news. Scandinavian Journal of Management, 21, 209–233.
33.
KosteraM. (2008). Introduction to the trilogy: Mythologies of organizational everyday life. In Organizational Olympians (pp. 1–8). London: Palgrave Macmillan.
34.
KroezeR.KeulenS. (2013). Leading a multinational is history in practice: The use of invented traditions and narratives at AkzoNobel, Shell, Philips and ABN AMRO. Business History, 55, 1265–1287.
35.
LawrenceT. B.SuddabyR. (2006). Institutions and institutional work. In CleggR.HardyC.LawrenceT. B.NordW. R. (Eds.), Handbook of organization studies, 2nd edition (pp. 215–254). London: SAGE Publications.
36.
LevyO. (2006) Ten years to Teva’s Copaxone – sales reach 5 Billion Dollars, Maariv, March8 [Hebrew].
37.
LincolnB. (1989). Discourse and the construction of society: Comparative studies of myth, ritual, and classification. New York: Oxford University Press.
38.
LincolnB. (1999). Theorizing myth: Narrative, ideology, and scholarship. Chicago: University of Chicago Press.
39.
MalschB.GendronY. (2009). Mythical representation of trust in auditors and the preservation of social order in the financial community. Critical Perspectives on Accounting, 20, 735–750.
40.
MazzaC.AlvarezJ. L. (2000). Haute couture and prêt-à-porter: The popular press and the diffusion of management practices. Organization Studies, 21, 567–588.
41.
MillsA. J.SuddabyR.FosterW. M.DureposG. (2016). Re-visiting the historic turn 10 years later: Current debates in management and organizational history – an introduction. Management & Organizational History, 11(2), 67–76.
42.
MirowskiP. (2008). Livin’ with the MTA. Minerva, 46, 317–342.
43.
ParkerL. (2011). University corporatisation: Driving redefinition. Critical Perspectives on Accounting, 22, 434–450.
44.
PentlandB. T. (1993). Getting comfortable with the numbers: Auditing and the micro-production of macro-order. Accounting, Organizations and Society, 18, 605–620.
45.
PowersJ. B.CampbellE. G. (2011). Technology commercialization effects on the conduct of research in higher education. Research in Higher Education, 52, 245–260.
46.
RawlinsJ. D. (2014). Mythologizing change: Examining rhetorical myth as a strategic change management discourse. Business and Professional Communication Quarterly, 77, 453–472.
47.
RhotenD.PowellW. W. (2007). The frontiers of intellectual property: Expanded protection versus new models of open science. Annual Review of Law and Social Science, 3, 345–373.
RowlinsonM.HassardJ. (1993). The invention of corporate culture: A history of the histories of Cadbury. Human Relations, 46, 299–326.
50.
Ruth and Uriel Arnon, A legacy of scientific discovery. (2015). Weizmann International Magazine of Science and People, 7, 16–19.
51.
SampatB. (2002). Private parts: Patents and academic research in the twentieth century. Paper prepared for Research Symposium of the ‘Next Generation’ of Leaders in Science and Technology Policy, AAAS and CSPO.
52.
SapirA. (2017). Protecting the purity of pure research: Organizational boundary-work at an institute of basic research. Minerva, 55(1), 65–91.
53.
SewellG. (2001). What goes around, comes around: Inventing a mythology of teamwork and empowerment. Journal of Applied Behavioral Science, 37, 70–89.
54.
SmithA.RussellJ. (2016). Toward polyphonic constitutive historicism: A new research agenda for management historians. Management & Organizational History, 11, 236–251.
55.
SuddabyR.FosterW. M.TrankC. Q. (2010). Rhetorical history as a source of competitive advantage. Strategic Management, 27, 147–173.
56.
VaaraE.TienariJ.LaurilaJ. (2006). Pulp and paper fiction: On the discursive legitimation of global industrial restructuring. Organization Studies, 27, 789–813.
57.
Van RielC. B.FombrunC. J. (2007). Essentials of corporate communication: Implementing practices for effective reputation management. London: Routledge.
WeinrebG. (2013b). Copaxone’s inventors hope for improved treatment. Globes, March28.
60.
Weizmann drug nears full scale use. (1995). Enigma, a Journal of Science and Discovery, 1, 3.
61.
Weizmann Institute of Science (1994a, July25). Teva to submit Weizmann Institute drug for MS to US FDA for evaluation [Press release].
62.
Weizmann Institute of Science (1994b, October28). Weizmann Institute MS drug to be submitted for approval [Press release].
63.
Weizmann Institute of Science (1996, January28). ‘Women of Distinction’ award to two Weizmann Institute scientists [Press release].
64.
Weizmann Institute of Science (2007, October10). Israeli scientists identify genes that affect responses of multiple sclerosis patients to Copaxone [Press release].
65.
YanowD. (1992). Silences in public policy discourse: Organizational and policy myths. Journal of Public Administration Research and Theory, 2(4), 399–423.
